Cleaving pre-fusion state SARS-CoV-2 spike protein
US11746142B2 · kind B2 · utility
0Cited by
0References
1Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 28, 2021 |
| Grant date | Sep 5, 2023 |
| Priority date | — |
| Expiry date | Dec 7, 2041 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/26
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
Disclosed is producing recombinant SARS-CoV-2 spike protein in a pre-fusion state, using furin knock out or knockdown mammalian cells (such as HEK293, CHO or other mammalian cells) and using them to generate antibodies and related binding agents. The antibodies/binding agents can be used in SARS-CoV-2 detection assays or in diagnosis of active or prior infection with SARS-CoV-2; in prophylaxis or as a therapeutic; or for prophylactic or therapeutic use against coronaviruses related to SARS-CoV-2.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.